Schroder Ventures' second International Life Sciences fund has invested $7.5m (€8.15m) in Affibody, the Swedish drug technology firm.
Affibody raised a total of $28m in its third round of fundraising. International Biotechnology Trust, the London Stock Exchange-listed investment firm advised by Schroder Ventures Life Sciences, invested $3.7m in the financing round. Kate Bingham, general partner at Schroder Ventures Life Sciences, who will join the board of Affibody, said: "Affibody has a unique proprietary platform, with very broad applications and clear revenue streams, as well as several strategic partnerships that will enable it to leverage its already leading market position."
